--- source_url: https://hangovr180.com/science/claims/gaba-receptor-alcohol.md canonical_url: https://hangovr180.com/science/claims/gaba-receptor-alcohol generated_at: 2026-06-28T19:53:17Z build_id: ebfcfef page_type: science-leaf claim_ids: [SF-31, SF-29, SF-25] --- # GABA RECEPTOR AND ALCOHOL *The GABA-A receptor is the brain's main inhibitory receptor, alcohol enhances its activity in the first hour of drinking, and the compensatory down-regulation that follows is what drives the next-day anxiety the H180 mood-balance claim addresses.* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ## What the GABA-A Receptor Does GABA (gamma-aminobutyric acid) is the brain's main inhibitory neurotransmitter. When GABA binds to the GABA-A receptor on a neuron, the receptor opens a chloride channel that hyperpolarizes the neuron and makes it less likely to fire. The net effect is to quiet down neural activity. The GABA-A receptor is also where benzodiazepines, barbiturates, propofol, and several other sedative-class drugs act -- they enhance the receptor's response to its own neurotransmitter[2]. Alcohol enhances GABA-A receptor activity through a binding site distinct from the benzodiazepine site. The first-hour-of-drinking experience -- the relaxation, the social ease, the mild sedation -- is largely a GABA-A potentiation effect. This is well-mapped pharmacology and is consistent across the published alcohol literature[2][3]. ## The Compensatory Down-Regulation > **Claim [SF-31]:** Provides relief from occasional anxiety from moderate alcohol use. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The brain does not tolerate sustained over-stimulation of any neurotransmitter system without compensation. Over a few hours of alcohol exposure, neurons down-regulate GABA-A receptor expression and up-regulate glutamate (excitatory) receptors to balance against the GABA potentiation. This is an adaptive response on the time scale of hours, and it is reversible on the time scale of days for moderate exposure and longer for heavy chronic exposure[3]. When alcohol clears from the brain, the compensation does not unwind instantly. The brain is left with a temporarily down-regulated inhibitory system and a temporarily up-regulated excitatory system. The result is the jittery, edge-of-panic feeling that some drinkers get even after one or two drinks the night before[2][3]. The rebound mechanism is documented across the alcohol-pharmacology and withdrawal literature, in the published animal and human work at least. ## What DHM Does at the Receptor > **Claim [SF-29]:** Product promotes calm mood and relief from occasional anxiety by blocking alcohol-induced activation of GABA. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. DHM is a positive modulator at the GABA-A receptor benzodiazepine binding site, which is a separate site from the alcohol binding site. The 2012 UCLA paper from Shen and colleagues showed that DHM counteracts ethanol-induced GABA-A potentiation in rat brain tissue, blocks acute alcohol intoxication, prevents tolerance development, and reduces withdrawal-related anxiety and seizure susceptibility -- all without itself producing sedation at the relevant doses[1]. (this is the claim where I have the strongest personal subjective response to the formula, but the regulatory language has to stay grounded in the published mechanism literature.) The mechanism that distinguishes DHM from benzodiazepines is that DHM binding at the benzodiazepine site blocks alcohol's effect at the alcohol site rather than amplifying GABA signaling generally. This is why DHM does not sedate at doses that block alcohol's GABA effects. ## The Hippocampal Gephyrin Story > **Claim [SF-25]:** Product promotes calm mood and relief from occasional anxiety by blocking activation of GABA. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. A 2020 follow-up study looked at DHM's effect inside the hippocampus and found that DHM modulation of GABAergic transmission improved anxiety behavior in mice and helped restore gephyrin levels (a structural protein that anchors GABA-A receptors at the synapse and that gets disrupted by chronic alcohol exposure)[4]. The structural-protein effect is interesting because it points to DHM doing something at the synaptic-architecture level, not just at the receptor-binding level. ## What This Page Is Not Claiming We are not claiming DHM treats anxiety disorders, alcohol use disorder, or any clinical mood condition. The claim is bounded to occasional anxiety in the specific context of moderate alcohol use, where the GABA-rebound mechanism is what drives the symptoms and the published DHM mechanism literature is reasonable. The GABA mechanism is what makes the next-day mood story biological rather than psychological, adn the formula addresses both ends of the receptor swing. For the full DHM GABA mechanism, see [DHM and GABA Modulation](/science/dhm/gaba-modulation). For the closely related mood balance claim mapping, see [The Mood Balance Claim](/science/claims/mood-balance). ## Citations 1. [Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication](https://pmc.ncbi.nlm.nih.gov/articles/PMC3292407/). PMC3292407. 2. [Alcohol Use Disorders and Current Pharmacological Therapies -- The Role of GABA-A Receptors](https://pmc.ncbi.nlm.nih.gov/articles/PMC4125717/). PMC4125717. 3. [GABAergic Signaling in Alcohol Use Disorder and Withdrawal -- Pathological Involvement and Therapeutic Potential](https://pmc.ncbi.nlm.nih.gov/articles/PMC10623140/). PMC10623140. 4. [Modulation of Hippocampal GABAergic Neurotransmission and Gephyrin Levels by Dihydromyricetin Improves Anxiety](https://pmc.ncbi.nlm.nih.gov/articles/PMC7364153/). PMC7364153. ## Read Next - [DHM and GABA Modulation](/science/dhm/gaba-modulation) - [The Mood Balance Claim](/science/claims/mood-balance) - [Neuroinflammation Explained](/science/claims/neuroinflammation) - [The Claims -- The Hub](/science/claims) **Written by Mark Scott** - Co-Formulator, Hangovr180® | Co-Inventor, [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1) Mark Scott conducted approximately 150 personal formulation tests over six months to develop the H180 ingredient combination. [Editorial standards](/editorial-standards) --- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Hangovr180® is a dietary supplement. Individual results may vary. Consult your healthcare provider before use if you have any medical conditions or take medications. [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1). Canonical: https://hangovr180.com/science/claims/gaba-receptor-alcohol